TORONTO, March 6, 2014 /CNW/ - Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, is pleased to announce that each of the nominees proposed as directors in the management information circular dated January 31, 2014 was duly elected as a director of Microbix by a majority of the votes cast by shareholders present in person or by proxy at the Annual Meeting of Shareholders held in Toronto, Ontario on March 5, 2014.
The voting results are detailed below:
| Nominee | For | % For | Withheld | % Withheld | ||||||||
| Peter M. Blecher | 28,333,628 | 99.42 | 165,585 | 0.58 | ||||||||
| Mark A. Cochran | 27,683,328 | 97.14 | 815,885 | 2.86 | ||||||||
| Vaughn C. Embro-Pantalony | 28,334,213 | 99.42 | 165,000 | 0.58 | ||||||||
| William J. Gastle | 28,334,913 | 99.42 | 164,300 | 0.58 | ||||||||
| Andrew C. Pollock | 28,199,713 | 98.95 | 299,500 | 1.05 | ||||||||
| Joseph D. Renner | 28,333,628 | 99.42 | 165,585 | 0.58 | ||||||||
| Martin Marino | 28,336,213 | 99.43 | 163,000 | 0.57 | ||||||||
| Cameron Groome | 28,199,713 | 98.95 | 299,500 | 1.05 |
About Microbix Biosystems
Microbix Biosystems Inc. specializes in the development of biological
solutions, including products for vaccine and diagnostics markets
worldwide. The company owns intellectual property for an approved
biological drug, a vaccine technology and an animal reproduction
technology. Established in 1988, Microbix is headquartered in Toronto.
Microbix' pipeline of innovative technologies and products includes LumiSort® semen sexing technology for the livestock industry, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in influenza vaccine manufacture.
Please visit www.sedar.com for recent Microbix Biosystems Inc. filings on its pipeline products and financial information.
SOURCE Microbix Biosystems Inc.
Visit www.microbix.com or contact: Vaughn C. Embro-Pantalony, CEO, (905) 361-8910 (ext. 350) or Charles Wallace, CFO (905) 361-8910 (ext. 255).
Copyright CNW Group 2014